Scienture (SCNX) announces the initiation of supply chain activities by its wholly owned subsidiary Scienture to manufacture launch quantities of Arbli Oral Suspension, 10 mg/mL for the intended commercial launch of the product in July 2025. Scirenture’a contract manufacturing partner, Saptalis Pharmaceuticals, for Arbli has indicated to Scienture that Saptalis has the materials and capabilities to produce the batches and supply product inventory in time for the target commercial launch. In addition, Scienture has also entered into agreements with strategic partners for warehousing and distributing the product to the market through various wholesalers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCNX:
- Scienture Holdings Divests Subsidiaries to Tollo Health
- Scienture divests Integra Pharma Solutions, Bonum Health, Softell for $5M
- Scienture files to sell 2.64M shares of common stock for holders
- Scienture CEO says focused on execution, growth, expansion for years ahead
- Scienture appoints Rath as CCO, enters agreement with Syneos